These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 33754020)

  • 1. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
    Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
    Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
    [No Abstract]   [Full Text] [Related]  

  • 2. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
    Stefansson M; Nygren P
    Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
    Nagashima M; Ooshiro M; Moriyama A; Sugishita Y; Kadoya K; Sato A; Kitahara T; Takagi R; Urita T; Yoshida Y; Tanaka H; Oshiro T; Okazumi S; Katoh R
    Support Care Cancer; 2014 Jun; 22(6):1579-84. PubMed ID: 24452412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
    Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
    Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
    Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
    Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
    Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
    Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
    Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
    Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
    Yildirim N; Cengiz M
    Support Care Cancer; 2020 Oct; 28(10):4781-4788. PubMed ID: 31974772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
    Lee S; Ma C; Shi Q; Kumar P; Couture F; Kuebler P; Krishnamurthi S; Lewis D; Tan B; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF; Meyerhardt JA
    J Clin Oncol; 2023 Feb; 41(5):1079-1091. PubMed ID: 36367997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
    Okamoto K; Nozawa H; Emoto S; Murono K; Sasaki K; Ishihara S
    Support Care Cancer; 2023 Oct; 31(12):660. PubMed ID: 37897532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
    Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M
    Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
    Oh PJ; Lee JR; Kim SK; Kim JH
    Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
    Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
    BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
    Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.
    Nepal MR; Taheri H; Li Y; Talebi Z; Uddin ME; Jin Y; DiGiacomo DF; Gibson AA; Lustberg MB; Hu S; Sparreboom A
    Cancer Res Commun; 2022 Nov; 2(11):1334-1343. PubMed ID: 36506732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
    Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function.
    Yang Y; Luo L; Cai X; Fang Y; Wang J; Chen G; Yang J; Zhou Q; Sun X; Cheng X; Yan H; Lu W; Hu C; Cao P
    Free Radic Biol Med; 2018 May; 120():13-24. PubMed ID: 29530794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
    Kotaka M; Iwamoto S; Satake H; Sakai D; Kudo T; Fukunaga M; Konishi K; Ide Y; Ikumoto T; Tsuji A; Sano Y; Kato T; Sugimoto N; Satoh T; Kanazawa A; Kurata T; Yamanaka T; Tomita N
    Int J Clin Oncol; 2020 Aug; 25(8):1515-1522. PubMed ID: 32409917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.